Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study.
Macchia G, Pezzulla D, Campitelli M, Russo D, Ronzino G, Lucci S, Salutari V, Di Stefano A, Balcet V, Epifani V, Perrucci E, Marchetti C, Distefano MG, Palluzzi E, Autorino R, De Luca V, Giannini R, Rinaldi R, Russo SA, Cilla S, Fagotti A, Gambacorta MA, Scambia G, Deodato F, Ferrandina G. Macchia G, et al. Among authors: palluzzi e. Int J Radiat Oncol Biol Phys. 2024 Sep 8:S0360-3016(24)03369-8. doi: 10.1016/j.ijrobp.2024.09.010. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39255875
Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Boccia SM, Sassu CM, Ergasti R, Vertechy L, Apostol AI, Palluzzi E, Fagotti A, Scambia G, Marchetti C. Boccia SM, et al. Among authors: palluzzi e. Drug Des Devel Ther. 2024 Jun 7;18:2021-2032. doi: 10.2147/DDDT.S451223. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38863768 Free PMC article. Review.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, Gori S, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Musacchio L, et al. Among authors: palluzzi e. Gynecol Oncol. 2024 May;184:24-30. doi: 10.1016/j.ygyno.2024.01.022. Epub 2024 Jan 25. Gynecol Oncol. 2024. PMID: 38277918
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: palluzzi e. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
New medical approaches in advanced ovarian cancer.
Corrado G, Palluzzi E, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. Corrado G, et al. Among authors: palluzzi e. Minerva Med. 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Minerva Med. 2019. PMID: 31124637 Review.
19 results